Source-grounded facts extracted from PharmaCyte Biotech, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PharmaCyte Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A), 5810(c)(3)(H)).
“In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until June 1, 2026 (the “Compliance Date”), to regain compliance”
PharmaCyte Biotech, Inc. engaged CBIZ CPAs P.C. as its auditor.
“On February 21, 2025, the Audit Committee of the Company’s Board of Directors accepted the resignation of Marcum and approved the engagement of CBIZ CPAs P.C. to serve as the Company’s independent registered public accounting firm.”
Marcum LLP resigned as auditor of PharmaCyte Biotech, Inc..
“(the “Company”) was notified by Marcum LLP (“Marcum”) that Marcum resigned as the independent registered accounting firm of the Company. Based on information provided by Marcum, effective November 1, 2024, CBIZ CPAs P.C. acquired the attest business of Marcum. On February 21, 2025, the Audit Committee of the Company’s Board of Directors accepted the resignation of Marcum and approved the engagement of CBIZ CPAs P.C.”
PharmaCyte Biotech, Inc. shareholders approved Approval of Executive Compensation at the 2024-04-29 meeting.
“Proposal 3. Approval of Executive Compensation. The approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. For Against Abstain Non-Votes Broker Non-Votes 1,922,352 186,215 50,866 0 2,355,454”
PharmaCyte Biotech, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2024-04-29 meeting.
“Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm. The ratification of the selection by the audit committee of the board of directors of Marcum LLP as the independent registered public accounting firm of the Company for the fiscal year ending April 30, 2024. For Against Abstain 4,387,273 109,167 18,447”
PharmaCyte Biotech, Inc. shareholders approved Election of Directors at the 2024-04-29 meeting.
“Proposal 1. Election of Directors. The election of five directors, each to hold office until the annual meeting of stockholders for the year ended April 30, 2025 or until their respective successor is elected and qualified. Nominee For Withheld Broker Non-Votes Joshua N. Silverman 1,892,894 266,539 2,355,454 Jonathan L. Schechter 2,064,472 94,961 2,355,454 Michael M. Abecassis 1,579,782 579,651 2,355,454 Robert Weinstein 2,022,363 137,070 2,355,454 Wayne R. Walker 2,060,785 98,648 2,355,454”
PharmaCyte Biotech, Inc. entered into Collaboration Agreement with Femasys Inc. (effective 2023-11-14).
“ith Femasys Inc. (“Femasys”) , pursuant to which it agreed to purchase from Femasys (i) senior unsecured convertible notes (the “Notes”) in an aggregate principal amount of $5,000,000, convertible into shares of Femasys common stock, par value”
PharmaCyte Biotech, Inc. entered into Registration Rights Agreement with Femasys Inc..
“ith Femasys Inc. (“Femasys”) , pursuant to which it agreed to purchase from Femasys (i) senior unsecured convertible notes (the “Notes”) in an aggregate principal amount of $5,000,000, convertible into shares of Femasys common stock, par value”
PharmaCyte Biotech, Inc. entered into Purchase Agreement with Femasys Inc. valued at $5,000,000 (effective 2023-11-14).
“On November 14, 2023, PharmaCyte Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Femasys Inc. (“Femasys”)”
PharmaCyte Biotech, Inc. engaged Marcum LLP as its auditor.
“On November 5, 2023, the Company engaged Marcum LLP (“Marcum”) as its new independent registered public accounting firm”
PharmaCyte Biotech, Inc.: Increased authorized common stock from 133,333,334 to 200,000,000 shares (effective 2023-09-06).
“the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Articles of Incorporation, as amended (the “Charter”), to increase the total number of authorized shares of the Company’s common stock from 133,333,334 to 200,000,000. On September 6, 2023, the Company filed the Amendment with the Secretary of State of the State of Nevada with immediate effect.”
PharmaCyte Biotech, Inc. shareholders approved Approval of the Increase of Authorized Shares of Common Stock (Charter Amendment) at the 2023-08-31 meeting.
“Proposal 2. Approval of the Increase of Authorized Shares of Common Stock. The approval of an amendment to the Charter to increase the total number of authorized shares of common stock from 133,333,334 to 200,000,000: For Against Abstain 9,982,019 1,019,080 421,264”
PharmaCyte Biotech, Inc. shareholders approved Authorization of the Issuance of Shares (Nasdaq Listing Rule 5635(d)) at the 2023-08-31 meeting.
“Proposal 1. Authorization of the Issuance of Shares. The authorization, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of shares of the Company’s common stock underlying shares of convertible preferred stock and warrants issued by the Company pursuant to the terms of that certain Securities Purchase Agreement, dated May 9, 2023, by and between the Company and the investors named therein, in an amount equal to or in excess of 20% of the Company’s common stock outstanding before the issuance of such convertible preferred stock and warrants (including any amortization payments made to the holders of convertible preferred stock in the form of issuance of shares of common stock and upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants): For Against Abstain Broker Non-Votes 7,170,025 400,161 432,796 3,419,381”
Armanino LLP resigned as auditor of PharmaCyte Biotech, Inc..
“On August 1, 2023, PharmaCyte Biotech, Inc. (the “Company”) was informed by Armanino LLP (“Armanino”), the Company’s current independent registered public accounting firm, that Armanino will resign as the Company’s independent auditor (see below explanation for resignation which is not related to any actions taken by the Company) effective as of the earlier of (a) the date the Company engages a new independent registered public accounting firm or (b) the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024.”
PharmaCyte Biotech, Inc.: Approved an amendment to the bylaws to allow the Board to fix a record date for an adjourned or postponed meeting as permitted under Nevada law (effective 2023-07-14).
“On July 14, 2023, the board of directors (the “Board”) of PharmaCyte Biotech, Inc. (the “Company”) approved an amendment (the “Bylaw Amendment”) to the Company’s bylaws, as amended (the “Bylaws”), effective immediately. Pursuant to the Bylaw Amendment, the Board may fix a record date for an adjourned or postponed meeting as permitted under Nevada law.”
PharmaCyte Biotech, Inc. entered into Engagement Letter with Katalyst Securities LLC valued at cash fee equal to 6% of gross proceeds (effective 2023-05-09).
“In connection with the Private Placement, pursuant to an Engagement Letter, dated May 9, 2023, between the Company and Katalyst Securities LLC (the “Placement Agent”), the Company has agreed to pay the Placement Agent a cash fee equal to 6% of the gross proceeds from any sale of securities in the Private Placement.”
PharmaCyte Biotech, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate gross proceeds of approximately $35 million (effective 2023-05-09).
“On May 9, 2023, PharmaCyte Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell to the Investors (i) an aggregate of 35,000 shares of the Company’s newly-designated Series B convertible preferred stock with a stated value of $1,000 per share, initially convertible into up to 8,750,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a conversion price of $4.00 per share (the “Preferred Shares”), and (ii) warrants to acquire up to an aggregate of 8,750,000 shares of Common Stock (the “Warrants”) (collectively, the “Private Placement”).”
PharmaCyte Biotech, Inc. shareholders approved Non-binding advisory vote on frequency of future advisory votes on executive compensation at the 2022-12-28 meeting.
“Proposal 7. Approval of Frequency of Future Votes to Approve Executive Compensation The approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers. Every Year Every Two Years Every Three Years Abstain Broker Non-Votes 7,493,683 72,255 134,022 114,513 5,660,489”
PharmaCyte Biotech, Inc. shareholders approved Non-binding advisory vote to approve executive compensation at the 2022-12-28 meeting.
“Proposal 6. Approval of Executive Compensation. The approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. For Against Abstain Non-Votes Broker Non-Votes 6,554,590 720,564 529,347 9,972 5,660,489”
PharmaCyte Biotech, Inc. shareholders approved Ratification of Armanino LLP as independent registered public accounting firm for fiscal year ending April 30, 2023 at the 2022-12-28 meeting.
“Proposal 5. Ratification of Selection of Independent Registered Public Accounting Firm. The ratification of the selection by the audit committee of the Board of Armanino LLP as the independent registered public accounting firm of the Company for the fiscal year ending April 30, 2023. For Against Abstain 13,124,245 256,083 94,634”
PharmaCyte Biotech, Inc. shareholders approved Approval of amendment to Charter to increase authorized shares of common stock from 33,333,334 to 133,333,334 at the 2022-12-28 meeting.
“Proposal 4. Approval of the Increase of Authorized Shares of Common Stock The approval of an amendment to the Charter to increase the total number of authorized shares of common stock from 33,333,334 to 133,333,334. For Against Abstain 11,020,851 2,399,825 54,286”
PharmaCyte Biotech, Inc. shareholders approved Approval of amendment to Articles of Incorporation to effect a reverse stock split at the 2022-12-28 meeting.
“Proposal 3. Approval of Reverse Stock Split. The approval of an amendment to the Company’s Articles of Incorporation, as amended (the “Charter”) to effect a reverse stock split of the Company’s common stock at a ratio of one new share for every five to twenty shares outstanding. For Against Abstain 11,385,563 2,067,045 22,354”
PharmaCyte Biotech, Inc. shareholders approved Approval of PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan at the 2022-12-28 meeting.
“Proposal 2. Approval of PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan The approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan. For Against Abstain Broker Non-Votes 6,532,612 1,162,890 118,971 5,660,489”
PharmaCyte Biotech, Inc. shareholders approved Election of five directors to hold office until 2023 annual meeting at the 2022-12-28 meeting.
“Proposal 1. Election of Directors. The election of five directors, each to hold office until the 2023 annual meeting of stockholders or until their respective successor is elected and qualified. Nominee For Withheld Broker Non-Votes Joshua N. Silverman 7,462,403 352,070 5,660,489 Jonathan L. Schechter 7,475,332 339,141 5,660,489 Michael M. Abecassis 7,381,147 433,326 5,660,489 Robert Weinstein 7,443,492 370,981 5,660,489 Wayne R. Walker 7,421,985 392,488 5,660,489”
PharmaCyte Biotech, Inc.: Removed cumulative voting provision for director elections and replaced with plurality voting (effective 2022-11-14).
“On November 14, 2022, the Board approved an amendment (the “Bylaw Amendment”) to the Company’s bylaws, as amended (the “Bylaws”), effective immediately. Pursuant to the Bylaw Amendment, the provision of the Bylaws allowing for cumulative voting in connection with the election of directors, which was invalid in the Bylaws, was removed and replaced with a provision allowing for the election of directors only by means of a plurality.”
Robert Weinstein was appointed as Director at PharmaCyte Biotech, Inc..
“On November 14, 2022, the board of directors (the “Board”) of PharmaCyte Biotech, Inc. (the “Company”) increased the size of the Board to six members and appointed Robert Weinstein to serve as a member of the Board, effective immediately.”
Jack E. Stover resigned as Director at PharmaCyte Biotech, Inc..
“On November 1, 2022, Jack E. Stover notified PharmaCyte Biotech, Inc. (the “Company”) of his decision to resign from the board of directors of the Company, effective immediately.”
Gerald W. Crabtree resigned as Chief Scientific Officer at PharmaCyte Biotech, Inc..
“On October 12, 2022 (the “Separation Date”), Gerald W. Crabtree, the Chief Scientific Officer of PharmaCyte Biotech , Inc. ( the “Company”), resigned from his position as an employee of the Company.”
Joshua N. Silverman was appointed as interim Chairman of the Board, interim Chief Executive Officer and interim President at PharmaCyte Biotech, Inc..
“Effective October 6, 2022, the Board appointed Joshua N. Silverman, a director on the Board since August 2022, as interim Chairman of the Board, interim Chief Executive Officer and interim President of the Company.”
Kenneth L. Waggoner resigned as Chief Executive Officer, President and General Counsel at PharmaCyte Biotech, Inc..
“Kenneth L. Waggoner, the Chief Executive Officer, President and General Counsel of PharmaCyte Biotech , Inc. ( the “Company”) resigned from his position as an employee of the Company and its direct and indirect subsidiaries and affiliates (collectively, the “Company Group”) and as a director on the Board of Directors of the Company (the “Board”).”
Stover was appointed as director at PharmaCyte Biotech, Inc..
“effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.”
Farb was appointed as director at PharmaCyte Biotech, Inc..
“effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.”
Allen was appointed as director at PharmaCyte Biotech, Inc..
“effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.”
Silverman was appointed as director at PharmaCyte Biotech, Inc..
“effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.”
Schechter was appointed as director at PharmaCyte Biotech, Inc..
“effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.”
Mr. Trujillo resigned as director at PharmaCyte Biotech, Inc..
“effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.”
Dr. Crabtree resigned as director at PharmaCyte Biotech, Inc..
“effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.”
Mr. Liquard resigned as director at PharmaCyte Biotech, Inc..
“effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.”
Dr. Tong resigned as director at PharmaCyte Biotech, Inc..
“effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.”
Dr. Matthias Löhr resigned as director at PharmaCyte Biotech, Inc..
“effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.”
Matthias Löhr was appointed as Director at PharmaCyte Biotech, Inc..
“On March 31, 2022, the Board of Directors ("Board") of PharmaCyte Biotech, Inc., a Nevada corporation ("Company"), appointed Matthias Löhr, MD ("Dr. Löhr") to the Board to fill a vacancy”
Thomas C.K. Yuen departed as Director at PharmaCyte Biotech, Inc..
“vacancy created by the recent death of Thomas C.K. Yuen”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.